Home  |  Contact

Cellosaurus BFTC-905-DOXO-II (CVCL_4V69)

[Text version]
Cell line name BFTC-905-DOXO-II
Accession CVCL_4V69
Resource Identification Initiative To cite this cell line use: BFTC-905-DOXO-II (RRID:CVCL_4V69)
Comments Population: Chinese; Taiwan.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1083 (BFTC-905)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

PubMed=25566959; DOI=10.1007/s13277-014-2959-9
Greife A., Tukova J., Steinhoff C., Scott S.D., Schulz W.A., Hatina J.
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
Tumor Biol. 36:3293-3300(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_4V69
Encyclopedic resources Wikidata; Q54796208
Entry history
Entry creation14-Dec-2015
Last entry update05-Oct-2023
Version number13